答：根据近期市场行情，VC 产品价格整体保持稳定。产品价格 受原材料成本、市场供需关系、行业库存等多重因素综合影响，具 有不确定性。从目前来看，下游需求端保持增长。公司对二季度的 市场展望持谨慎乐观态度，并将继续通过精益管理控制成本，提升 产品竞争力。具体的价格走势受宏观环境影响较大，敬请投资者注 意投资风险。 4. 主营业务原料药及中间体、微生物蛋白今年的经营目标？ 江西富祥药业股份有限公司 投资者关系活动记录表 | 证券代码：300497 | 编号：20260302 | 证券简称：富祥药业 | | --- | --- | --- | | | □ 特定对象调研 □ 分析师会议 | | | 投资者关系活动 | 媒体采访 业绩说明会 □ □ | | | 类别 | 新闻发布会 路演活动 □ √ | | | | 现场参观 其他 □ □ | | | 参与单位名称及 | 国金证券、中金基金、博时基金、摩根基金、中航基金、东方基金、 | | | 人员姓名 | 华福资管、中哲物产、中加基金、紫金信托、湖南长心私募、德邦 | | | | 基金、交银理财、玄元投资、盘京投资、海富通基金、光大永明资 | | | | 产、上海信托 ...

Core Viewpoint - Fujian Pharmaceutical is experiencing significant operational improvement in 2025, driven primarily by its lithium battery electrolyte additive business, which has benefited from rising demand in the power battery and energy storage markets [1][5]. Group 1: Business Performance - The lithium battery electrolyte additive products, such as VC and FEC, saw a substantial price increase in Q4 2025, with battery-grade VC averaging 164,000 yuan/ton, up over 200% from the low in September [1]. - The pharmaceutical manufacturing segment has optimized steadily despite intense market competition, with a decrease in the price of key raw materials like 6-APA, leading to an improvement in gross margins [1][2]. - The company reported a net loss of 39 million to 57 million yuan for the year, marking a significant reduction in losses, and achieved profitability in Q4, indicating a positive trend in operational performance [5]. Group 2: Future Outlook - The synthetic biological microbial protein business achieved critical breakthroughs in 2025, obtaining multiple certifications that pave the way for large-scale production, although its contribution to 2025's performance is limited [3]. - For 2026, the company plans to consolidate its market position in pharmaceuticals, leverage price increases in the new energy sector, and accelerate the development of the microbial protein project to enhance capacity and market presence [3].

Core Viewpoint - Fuxiang Pharmaceutical (300497.SZ) expects a loss of 39 million to 57 million yuan in 2025, with a non-recurring loss of 69 million to 87 million yuan, and operating revenue projected between 1.15 billion to 1.25 billion yuan [1] Group 1: Business Performance - The company anticipates significant improvement in overall operating performance driven by the synergistic development of its three main business segments in 2025 [1] - The lithium battery electrolyte additive business is expected to benefit from the continuous growth in demand for power batteries and the rapid explosion in energy storage battery demand, leading to a substantial increase in prices of VC and FEC products in Q4 [1] - In the pharmaceutical manufacturing sector, despite intense market competition, the decline in prices of key raw materials such as 6-APA for core products like Tazobactam and Sulbactam is expected to enhance the gross margin of the pharmaceutical business [1] Group 2: Financial Projections - The projected operating revenue for 2025 is estimated to be between 1.15 billion and 1.25 billion yuan [1] - The expected net profit attributable to shareholders of the listed company is anticipated to significantly reduce losses year-on-year due to the improved profitability of the aforementioned business segments [1]

Core Viewpoint - Fuxiang Pharmaceutical (300497) anticipates significant improvement in its financial performance for 2025, projecting revenue between 1.15 billion to 1.25 billion yuan and a reduced net loss of 39 million to 57 million yuan compared to 2024, with a turnaround expected in Q4 2025 [1] Group 1: Business Segments - The company has been deeply involved in the pharmaceutical intermediates and active pharmaceutical ingredients sectors, while also expanding into lithium battery electrolyte additives and synthetic biology microbial protein businesses [1] - The lithium battery electrolyte additive segment is expected to be the main driver of revenue growth in 2025, benefiting from rising demand in the power battery and energy storage markets [1] - The average price of battery-grade VC has increased over 200% since the low point in September 2025, reflecting a tight supply-demand balance in the industry [2] Group 2: Financial Performance - Fuxiang Pharmaceutical has leveraged its scale production capacity and cost control advantages to benefit from the current price increase cycle, resulting in significant improvements in product shipment volume, sales revenue, and gross margin [2] - The pharmaceutical manufacturing segment has seen a reduction in the price of key raw materials, which has alleviated cost pressures and improved gross margins year-on-year [2] - The company has reduced asset impairment provisions, enhancing asset value stability as profitability improves in both its new energy and pharmaceutical businesses [2] Group 3: Future Growth Potential - The synthetic biology microbial protein business has achieved critical breakthroughs in 2025, with multiple certifications obtained, paving the way for compliance from research to large-scale production [3] - Although the microbial protein business is expected to contribute limited revenue in 2025, it is anticipated to become a core profit growth point as production capacity is released and market expansion progresses [3] - The company aims to consolidate its market position in pharmaceuticals, capitalize on price increases in the new energy sector, and accelerate the construction and market deployment of its microbial protein project to drive high-quality development [3]

Core Viewpoint - Fuxiang Pharmaceutical is expected to significantly reduce its net loss in 2025, projecting a loss of 39 million to 57 million yuan, with a potential turnaround to profitability in Q4, driven by the synergy of its three main business segments: new energy, pharmaceutical manufacturing, and synthetic biology [1] Group 1: Business Performance - The new energy lithium battery electrolyte additive business is identified as the core driver of performance growth in 2025, benefiting from rising demand in the power battery and energy storage markets, leading to a substantial price increase for products like VC and FEC in Q4 [1] - The pharmaceutical manufacturing segment has optimized its operations despite intense market competition, with a decrease in the price of key raw materials like 6-APA alleviating cost pressures and improving gross margins [2] - The synthetic biology segment achieved significant milestones in 2025, obtaining key certifications that enable the transition from laboratory research to large-scale production, indicating a successful compliance pathway [2] Group 2: Future Outlook - For 2026, the company aims to consolidate its market position in the pharmaceutical sector while focusing on cost reduction and efficiency improvements [3] - The company plans to capitalize on the rising product prices in the new energy sector by enhancing production capacity through technological upgrades [3] - The company will accelerate the development of the synthetic biology protein project, expanding its application scenarios and enhancing its market presence both domestically and internationally [3]

Core Viewpoint - The company, Fuxiang Pharmaceutical, anticipates a significant net loss for the year 2025, with projections indicating a loss of 39 million to 57 million yuan for net profit attributable to shareholders, and a loss of 69 million to 87 million yuan for net profit after deducting non-recurring gains and losses [1] Group 1: Business Performance - The company expects its overall operating performance to improve in 2025 due to the synergistic development of its three main business segments, leading to a substantial reduction in net loss compared to the previous year [1] - The lithium battery electrolyte additive business is expected to benefit from the continuous growth in demand for power batteries and the rapid explosion in demand for energy storage batteries, resulting in a significant price increase for products like VC and FEC in the fourth quarter [1] - In the pharmaceutical manufacturing sector, despite intense market competition, the decline in prices of key raw materials such as 6-APA for core products like Tazobactam and Sulbactam is expected to enhance the gross margin of the pharmaceutical business [1] Group 2: Financial Impact - The company estimates that non-recurring gains and losses will impact net profit by approximately 30 million yuan during the reporting period [1]

Group 1: Financial Performance and Product Impact - The price of 6-APA has decreased by approximately 45% to 180 RMB/kg as of January 19, 2026, positively impacting the gross margin of core products like Tazobactam and Sulbactam, which together account for about 40% of the company's revenue in 2024 [2][3] - The new production process for Tazobactam is expected to lower production costs while enhancing product quality, thus improving market competitiveness [3] Group 2: Market Demand and Product Synergy - Piperacillin, a key β-lactam antibiotic, is crucial for combination formulations that address bacterial resistance, with its demand closely tied to downstream formulations [4] - The market demand for Piperacillin is driven by ongoing clinical needs for anti-infection treatments and the increasing application of combination formulations due to rising antibiotic resistance [4] Group 3: Capacity Expansion and Strategic Planning - The company plans to expand VC (Vinyl Carbonate) production capacity from 8,000 tons/year to 10,000 tons/year, with a long-term goal of 20,000 tons/year, driven by the growing demand in the battery market [5] - The expansion is characterized by low investment and quick response to market needs, minimizing overall risk while maximizing economic benefits [5] Group 4: Innovative Protein Development - The "Weiran Protein" product line focuses on high-protein, high-fiber, and low-residue applications, targeting markets such as artificial meat and health foods [6][7] - The company has established competitive advantages in the synthetic biology protein sector, including proprietary strains and advanced technology, positioning itself as a leader in the market [6][7] - Collaborations with academic institutions and the establishment of the "Weiran New Quality Protein Alliance" aim to drive market education and product innovation [7]

Group 1 - Jiangxi Fuxiang Pharmaceutical Co., Ltd. (stock code: 300497) has officially signed a strategic cooperation agreement with the pharmaceutical information and networking platform Yaorongquan, aiming for deep integration in the pharmaceutical and biomanufacturing sectors to promote technological innovation and industrialization [1][13] - The cooperation will focus on Fuxiang's three major industry segments: pharmaceuticals, new energy materials, and biomanufacturing, enhancing collaboration in product development, visual systems, key projects, and talent recommendations [8][20] - Fuxiang has established itself as a significant player in the biomanufacturing field, with its subsidiary Fuxiang Biotechnology being the first in China to achieve ton-level industrialization of new protein, with an annual production line capacity of 1,200 tons [2][15] Group 2 - Fuxiang Pharmaceutical has received approval from the National Health Commission, marking a milestone in its biomanufacturing development and positively impacting domestic food manufacturing and national food security [6][18] - The company operates in three main sectors: pharmaceuticals, new energy materials, and biomanufacturing, with a strong focus on antibiotic raw materials and lithium battery electrolyte additives [9][22] - In the biomanufacturing sector, Fuxiang is recognized as Asia's first company to achieve ton-level industrialization of filamentous fungal protein and has developed a new production strain with independent intellectual property rights, currently holding a national invention patent [10][23]

Group 1: Company Achievements and Certifications - The company’s Wei Ran protein has officially passed the National Health Commission's administrative approval, obtaining new food raw material certification, which serves as a significant milestone in its development [2][3] - The certification allows Wei Ran protein to enter the Chinese food market, establishing a "dual certification" global market framework, enhancing international competitiveness and risk resistance [3] - Wei Ran protein features a nutritional profile of "high protein, high dietary fiber, low fat, and zero cholesterol," meeting modern consumer demands for healthy diets [3] Group 2: Market and Industry Impact - The successful certification provides a replicable model for the approval and commercialization of the fungal protein industry in China, boosting industry confidence and attracting more capital and talent [3] - The development of Wei Ran protein aligns with national strategies for protein supply security and reducing reliance on imported soybeans, contributing to environmental sustainability [4] Group 3: Future Capacity and Business Strategy - The company plans to leverage its technological advantages and circular economy model to maintain industry leadership and expand both domestic and international markets [5] - Future capacity releases will focus on optimizing production processes and raw material costs, enhancing competitive advantages [5] Group 4: Business Performance and Growth Projections - The pharmaceutical manufacturing segment is expected to benefit from a 41% decrease in the price of 6-APA, alongside growing market demand for downstream products [6] - The lithium battery additive business is experiencing rapid price increases due to rising demand from energy storage and power battery sectors [7] - The company’s synthetic biology business has received approval for Wei Ran protein as a new food raw material, facilitating its commercialization and global market entry [7] Group 5: Risk Management and Investor Relations - All information disclosed by the company is based on official announcements, urging investors to make rational investment decisions and be aware of risks [8]

Group 1 - Muxi Co., Ltd. plans to issue 40.1 million shares with a strategic placement of 8.02 million shares, with the initial inquiry date set for December 2, 2025, and subscription date on December 5, 2025 [1] - Changguang Huaxin has reported uncertainty regarding the sales and profit contributions of several optical communication chips for the current year, despite recent growth in computing power demand [2] - Shida Group clarified that there is currently no business cooperation with Alibaba Cloud, addressing rumors circulating on online platforms [3] Group 2 - Jindike announced that it will not issue additional batches of quadrivalent influenza virus split vaccine this year, with approximately 1.56 million doses already certified for sale [4] - Industrial Fulian adjusted its share repurchase price ceiling from 19.36 RMB to 75 RMB per share, with a total of 7,697,400 shares repurchased so far [5] - Meiyan Jixiang's application for mineral resource review has been accepted, but there are still uncertainties regarding the evaluation results and subsequent approval processes [6] Group 3 - Yidong Electronics plans to invest 61.2 million RMB to acquire 51% of Shenzhen Guanding, aiming to expand into AI server liquid cooling products [7] - Jianlong Micro-Nano has terminated its major asset restructuring plans due to the conditions not being mature enough for the transaction [8][9] - Guangdian Yuntong won a bid for a 308 million RMB artificial intelligence application pilot base construction project [11]